AbbVie to acquire Apogee Therapeutics for <meta name=

0.9B cash for Apogee at 35.11/share, a 49.49% premium, to bolt-on a late-stage IL-13 immunology pipeline." /> 0.9B all-cash at 35.11/share on Monday June 22 — 49.49% premium to APGE's $90.38 Thursday close — APGE +~47% intraday as both boards unanimously approve, Q3 2026 close, EPS-accretive in 2032; $381.27M reciprocal termination fee" /> 0.9B cash for Apogee at 35.11/share, a 49.49% premium, to bolt-on a late-stage IL-13 immunology pipeline." /> 0.9B all-cash at 35.11/share on Monday June 22 — 49.49% premium to APGE's $90.38 Thursday close — APGE +~47% intraday as both boards unanimously approve, Q3 2026 close, EPS-accretive in 2032; $381.27M reciprocal termination fee" /> 0.9B cash for Apogee at 35.11/share, a 49.49% premium, to bolt-on a late-stage IL-13 immunology pipeline." />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.